2001 Results

People

  1. Motzer
    Motzer
  2. Hudis
    Hudis
  3. Kelsen
    Kelsen
  4. Saltz
    Saltz
  5. Norton
    Norton
  6. Bajorin
    Bajorin
  7. Kemeny
    Kemeny
  8. Scher
    Scher
  9. Ilson
    Ilson
  10. O'Reilly
    O'Reilly

Groups

  1. Department of Medicine (1218)
  2. Solid Tumor Oncology Division (929)
  3. Survivorship Research (432)
  4. Surgery (399)
  5. Hematologic Malignancies, Division of (340)
  6. Center for Hematologic Malignancies (328)
  7. Gastrointestinal Oncology Service (315)
  8. Epidemiology and Biostatistics (251)
  9. Genitourinary Oncology Service (233)
  10. Biostatistics Service (223)
  1. "antineoplastic combined chemotherapy protocols"
Formats
  1. Journal Article (1861)
  2. Conference Paper (49)
  3. Review (39)
  4. Editorial (17)
  5. Research Letter (15)
  6. Miscellaneous (8)
  7. Correspondence (6)
  8. Guidelines (5)
  9. Book Section (1)
Groups
  1. Department of Medicine (1218)
  2. Solid Tumor Oncology Division (929)
  3. Survivorship Research (432)
  4. Surgery (399)
  5. Hematologic Malignancies, Division of (340)
  6. Center for Hematologic Malignancies (328)

More Groups

People
  1. Nancy Kemeny (90)
  2. Robert Motzer (88)
  3. Clifford Hudis (83)
  4. David Kelsen (83)
  5. Leonard Saltz (79)
  6. Larry Norton (77)

More People

Years
  1. 2025 (46)
  2. 2024 (133)
  3. 2023 (122)
  4. 2022 (90)
  5. 2021 (11)
  6. 2020 (7)

More Years

Publications
  1. Journal of Clinical Oncology (279)
  2. Cancer (171)
  3. Clinical Cancer Research (78)
  4. Seminars in Oncology (59)
  5. Gynecologic Oncology (58)
  6. New England Journal of Medicine (58)

More Publications

Publishers
  1. American Society of Clinical Oncology (294)
  2. Elsevier Inc. (276)
  3. Wiley Blackwell (212)
  4. Springer (167)
  5. Oxford University Press (113)
  6. American Association for Cancer Research (108)

More Publishers

Results (2001)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Telaglenastat plus cabozantinib or everolimus for advanced or metastatic renal cell carcinoma: An open-label phase I trial
    Journal Article

    Meric-Bernsta, F.; Tannir, N. M.; Iliopoulos, O.; Lee, R. J.; Telli, M. L.; Fan, A. C.; DeMichele, A.; Haas, N. B.; Patel, M. R.; Harding, J. J.; more...
    Clinical Cancer Research (2022)

    Fulltext@MSK | Save
  • Local therapy outcomes and toxicity from the ATEMPT trial (TBCRC 033): A phase II randomized trial of adjuvant trastuzumab emtansine versus paclitaxel in combination with trastuzumab in women with stage I HER2-positive breast cancer
    Journal Article

    Bellon, J. R.; Tayob, N.; Yang, D. D.; Tralins, J.; Dang, C. T.; Isakoff, S. J.; DeMeo, M.; Burstein, H. J.; Partridge, A. H.; Winer, E. P.; more...
    International Journal of Radiation Oncology, Biology, Physics (2022)

    Fulltext@MSK | Save
  • A phase 2 trial of response-based radiation therapy for localized central nervous system germ cell tumors: Patterns of failure and radiation dosimetry for nongerminomatous germ cell tumors
    Journal Article

    Murphy, E. S.; Dhall, G.; Fangusaro, J.; Bartels, U.; Fouladi, M.; Shaw, D.; Khatua, S.; Hughes, C. W.; Panigraphy, A.; Ioakeim-Ioannidou, M.; more...
    International Journal of Radiation Oncology, Biology, Physics (2022)

    Fulltext@MSK | Save
  • Refining risk stratification in HR-positive/HER2-negative early breast cancer: How to select patients for treatment escalation?
    Review

    Morganti, S.; Marra, A.; Crimini, E.; D’Amico, P.; Zagami, P.; Curigliano, G.
    Breast Cancer Research and Treatment (2022)

    Fulltext@MSK | Save
  • Current approaches to management of newly diagnosed multiple myeloma
    Review

    Goel, U.; Usmani, S.; Kumar, S.
    American Journal of Hematology (2022)

    Fulltext@MSK | Save
  • Diet- and lifestyle-based prediction models to estimate cancer recurrence and death in patients with stage III colon cancer (CALGB 89803/Alliance)
    Journal Article

    Cheng, E.; Ou, F. S.; Ma, C.; Spiegelman, D.; Zhang, S.; Zhou, X.; Bainter, T. M.; Saltz, L. B.; Niedzwiecki, D.; Mayer, R. J.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Atezolizumab with enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer: A randomized phase 3 trial
    Journal Article

    Powles, T.; Yuen, K. C.; Gillessen, S.; Kadel, E. E. 3rd; Rathkopf, D.; Matsubara, N.; Drake, C. G.; Fizazi, K.; Piulats, J. M.; Wysocki, P. J.; more...
    Nature Medicine (2022)

    Fulltext@MSK | Save
  • Induction FOLFIRINOX for patients with locally unresectable pancreatic ductal adenocarcinoma
    Journal Article

    McIntyre, C. A.; Cohen, N. A.; Goldman, D. A.; Gonen, M.; Sadot, E.; O'Reilly, E. M.; Varghese, A. M.; Yu, K. H.; Balachandran, V. P.; Soares, K. C.; more...
    Journal of Surgical Oncology (2022)

    Fulltext@MSK | Save
  • Lenvatinib plus pembrolizumab for advanced endometrial cancer
    Journal Article

    Makker, V.; Colombo, N.; Casado Herráez, A.; Santin, A. D.; Colomba, E.; Miller, D. S.; Fujiwara, K.; Pignata, S.; Baron-Hay, S.; Ray-Coquard, I.; more...
    New England Journal of Medicine (2022)

    Fulltext@MSK | Save
  • Treatment exposure and discontinuation in the PALbociclib CoLlaborative Adjuvant Study of palbociclib with adjuvant endocrine therapy for hormone receptor-positive/human epidermal growth factor receptor 2-negative early breast cancer (PALLAS/AFT-05/ABCSG-42/BIG-14-03)
    Journal Article

    Mayer, E. L.; Fesl, C.; Hlauschek, D.; Garcia-Estevez, L.; Burstein, H. J.; Zdenkowski, N.; Wette, V.; Miller, K. D.; Balic, M.; Mayer, I. A.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save